Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Johnson & Johnson (NYSE:JNJ) from Outperform to Market Perform. Analyst Price Forecast Suggests 17.34% Upside As ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Digital magazine Jom's logo (left) and the Old Hill Street Police Station that now houses the office of the Ministry of Digital Development and Information (right). (Photos: Jom/MDDI) New ...

That said, one stock that continues to stand out is Johnson & Johnson JNJ. The pharmaceutical giant's stock hit new 52-week highs of nearly $170 on Tuesday, with JNJ now up +16% year to date.

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

Shares of Johnson & Johnson stock opened at $153.46 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52 week ...

Johnson & Johnson (NYSE:JNJ) traded flat in the premarket on Wednesday after the pharma giant exceeded Street forecasts for Q4 2024, mainly due to its Innovative Medicine unit, while its MedTech ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants ...

Johnson & Johnson forms a Death Cross as JNJ stock drops below key moving averages, signaling bearish momentum. Strategic moves in dermatology, including a licensing deal for eczema drug KP-723 ...

My last article on Johnson & Johnson (NYSE:JNJ) was published back in October 2024. That article was entitled “Johnson & Johnson: You Need To Look At This Chart ...

Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its ...

Johnson & Johnson’s JNJ wholly-owned subsidiary, Johnson & Johnson MedTech, recently announced its partnership with Nvidia to accelerate secure, real-time analysis of surgical data using ...